Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (<0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the Periodic Acid Schiff–positive, diastase-sensitive). The expression of steroid receptors (estrogen and progesterone receptors) has been variably reported (35% to 100% of the cases), whereas most studies reported low human epidermal growth factor receptor 2 positivity in GRCC. High androgen receptor positivity without androgen receptor splice variant-7 was reported in one recent study. Although sparse, the preliminary theranostic data on GRCC indicate the potential of targeted treatments in selected cases (antiandrogen, PIK3CA, and immune checkpoint inhibitors). Because of its rarity, the prognosis for GRCC patients remains controversial. Herein, we comprehensively appraise the epidemiological, morphologic, molecular, and clinical characteristics of this rare mammary malignancy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review

Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/glycogen-rich-clear-cell-carcinoma-of-the-breast-a-comprehensive-ll8O8vr32M

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000850
Publisher site
See Article on Publisher Site

Abstract

Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (<0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the Periodic Acid Schiff–positive, diastase-sensitive). The expression of steroid receptors (estrogen and progesterone receptors) has been variably reported (35% to 100% of the cases), whereas most studies reported low human epidermal growth factor receptor 2 positivity in GRCC. High androgen receptor positivity without androgen receptor splice variant-7 was reported in one recent study. Although sparse, the preliminary theranostic data on GRCC indicate the potential of targeted treatments in selected cases (antiandrogen, PIK3CA, and immune checkpoint inhibitors). Because of its rarity, the prognosis for GRCC patients remains controversial. Herein, we comprehensively appraise the epidemiological, morphologic, molecular, and clinical characteristics of this rare mammary malignancy.

Journal

Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health

Published: Oct 11, 2020

References

  • Comprehensive molecular portraits of human breast tumours
  • Glycogen-rich clear cell carcinoma of the breast: a light and electron microscopic study
  • Invasive ductal carcinoma of the breast with clear cell and pseudo-lactating changes
  • Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the US population
  • Glycogen-rich clear-cell carcinoma of the breast: a clinicopathologic and flow cytometric study
  • Early stages of clear cell (glycogen rich cell) invasive ductal carcinoma (IDC) of the breast: good or bad prognosis?
  • Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast
  • Molecular profiling of clear cell carcinoma of the breast reveals novel targetable biomarkers
  • 77PHep par 1 immunohistochemistry in glycogen-rich clear cell carcinoma of the breast
  • Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast
  • Fine needle aspiration cytology of glycogen-rich clear cell carcinoma of the breast: review of 37 cases with histologic correlation
  • Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer
  • Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases
  • Glycogen-rich clear cell carcinomas of the breast. A clinicopathologic and ultrastructural study
  • Glycogen-rich, clear cell breast cancer: with comments concerning other clear cell variants
  • Prognostic evaluation of epidermal growth factor receptor (EGFR) genotype and phenotype parameters in triple-negative breast cancers
  • Immunophenotypes of glycogen rich clear cell carcinoma
  • Glycogen-rich carcinomas of the breast display unique characteristics with respect to proliferation and the frequency of oligonucleosomal fragments
  • Solid glycogen-rich clear cell carcinoma of the breast (a light and ultrastructural study)
  • Glycogen-rich clear cell carcinoma of the breast: a solid variant with mucus. A light microscopic, immunohistochemical and ultrastructural study of a case
  • Glycogen-rich clear cell carcinoma of the breast: a case report and review of the literature
  • Glycogen-rich clear cell carcinoma of the breast. An autopsy case
  • Invasive mammary carcinoma with mixed invasive papillary and glycogen rich clear cell features
  • Glycogen-rich clear-cell breast carcinoma with neuroendocrine differentiation features
  • Intraductal glycogen-rich clear cell carcinoma of the breast: a rare presentation and review of the literature
  • A case of glycogen-rich clear cell carcinoma of the breast with extensive intraductal components and micrometastases to the axillary lymph node
  • Histopathological and immunohistochemical findings in a case of glycogen-rich clear cell carcinoma of the breast
  • Cytological analysis of glycogen-rich carcinoma of the breast: report of two cases
  • Glycogen-rich clear cell carcinoma of the breast: report of a case with fine-needle aspiration cytology and immunocytochemical and ultrastructural studies
  • Fine-needle aspiration cytology of glycogen-rich carcinoma of breast: report of a case and review of literature
  • Cytology of glycogen-rich (clear cell) carcinoma of the breast. A report of two cases
  • Apocrine carcinoma of the breast: a comprehensive review
  • Clear cell mammary malignant myoepithelioma with abundant glycogens
  • Glycogen-rich clear cell mammary malignant myoepithelioma
  • Malignant myoepithelioma of the breast: case report with review of literature
  • Clear cell ‘sugar’ tumor of the breast: another extrapulmonary site and review of the literature
  • PEComa: what do we know so far?
  • TFE3-expressing perivascular epithelioid cell tumor of the breast
  • A rare case of malignant epithelioid angiomyolipoma in multiple locations: multifocal disease or metastases?
  • Mammary angiomyolipoma
  • Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
  • Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer
  • The significance of GATA3 expression in breast cancer: a 10-year follow-up study
  • GATA3 mutations found in breast cancers may be associated with aberrant nuclear localization, reduced transactivation and cell invasiveness
  • Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples
  • Androgen receptor signaling pathways as a target for breast cancer treatment
  • Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review
  • Androgen receptor in breast cancer-clinical and preclinical research insights
  • Role of the androgen receptor in triple-negative breast cancer
  • Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype
  • Prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study
  • Predictive biomarker profiling of > 6000 breast cancer patients shows heterogeneity in TNBC, with treatment implications
  • TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer
  • Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer
  • A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
  • Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer
  • Expression of androgen receptor splice variants in clinical breast cancers
  • Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues
  • PD-L1 status in breast cancer: current view and perspectives
  • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
  • Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: a new clinical paradigm in the treatment of triple-negative breast cancer
  • Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer
  • Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma
  • Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
  • Tumour-intrinsic resistance to immune checkpoint blockade
  • PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition
  • Clinical imaging of glycogen-rich clear cell carcinoma of the breast: a case series with literature review
  • Glycogen-rich clear cell carcinoma of the breast: a case report
  • Glycogen rich clear cell carcinoma (GRCC) of the breast may not have a poor prognosis
  • Clear cell carcinoma of the breast: a rare breast cancer subtype—case report and literature review
  • Glycogen-rich clear cell carcinoma of the breast
  • Glycogen rich clear cell carcinoma of the breast: a rare subtype with good prognosis